Skip to main content
. 2015 Oct 14;6(39):41929–41943. doi: 10.18632/oncotarget.5861

Figure 3. Effect of (E)-4-(3-(3,5-dimethoxyphenyl)allyl)-2-methoxyphenol on the DNA binding activity of NF-κB and STAT3 and ffect of STAT3 inhibitor and NF-κB inhibitor on (E)-4-(3-(3,5-dimethoxyphenyl)allyl)-2-methoxyphenol-induced colon cancer cell growth.

Figure 3

A. & B. Colon cancer cells were treated with (E)-4-(3-(3,5-dimethoxyphenyl)allyl)-2-methoxyphenol (0-15 μg/ml) for 2 h, and then were lysed. Nuclear extract was incubated in binding reactions of ³²p-end-labeled oligo nucleotide containing the STAT3 or NF-κB sequence. The present EMSA results are representative for three experiments. C. & D. Cells were pretreated with NF-κB inhibitor PAO (0.1 μM) or STAT3 inhibitor Stattic (50 μM) for 1 h and then were treated with (E)-4-(3-(3,5-dimethoxyphenyl)allyl)-2-methoxyphenol for 24 h. Relative cell survival rate was determined by MTT assay. E. Whole cell extracts were analyzed by Western blotting using Fas, DR3 and β-actin antibodies. F. Effect of STAT3 inhibitor on the DNA binding activity of STAT3. Each band is representative for three experiments. *p < 0.05, indicates significant difference from control cells. #p < 0.05 indicates significant difference from (E)-4-(3-(3,5-dimethoxyphenyl)allyl)-2-methoxyphenol-treated cells.